Arkin Bio Ventures is the life sciences arm of Arkin Holdings, based in Israel. Launched in 2016, the fund backs breakthrough biotech companies developing novel therapeutics. It operates under the broader Arkin Capital platform, which manages over $2 billion in diversified healthcare assets.
Arkin Bio Ventures III closed in January 2026 with $100 million to invest in preclinical and early clinical-stage biotech companies. The fund is backed by major institutional LPs including Phoenix Insurance, Clal Insurance, and Amitim Pension Funds, alongside a large commitment from Arkin Capital itself. The strategy with Fund III is clear: fewer, higher-conviction bets in companies that can realistically reach a major value inflection point—clinical proof of concept in patients. Arkin expects to back 10–12 startups globally and will continue to rely on its deep scientific network to build strong syndicates, refine development plans, and drive collaborations with later-stage investors and pharma. This fund marks a stage shift from earlier vehicles, now focusing more on assets with human data in sight, and continues to build on Arkin’s track record in early-stage biotech.
Leadership
The fund is led by Managing Partner Pini Orbach, a veteran in life sciences investing with a deep scientific background. Orbach and his team bring hands-on operational support, investor syndicate building, and strategic biotech and pharma connections to every deal.
Investment Strategy
Arkin Bio Ventures follows a focused strategy centered on programs with validated targets, strong mechanistic rationale, and clear clinical development pathways. The team looks for programs that can move efficiently into and through early human studies, aiming to build value through early clinical proof points. They work closely with founding teams and co-investors to accelerate development and maximize exit optionality.
Notable Investments
Arkin Bio Ventures has backed a range of early-stage biotech companies in both Israel and globally, including Immunai, KAHR Medical, and Purple Biotech. Their portfolio reflects a deep commitment to biology-led innovation across high-impact disease areas.
Notable Exits
Several Arkin-backed companies have achieved successful exits, including acquired or IPO’d companies in immuno-oncology and targeted therapies, although specific recent exits from Fund II or III have not yet been disclosed publicly.
Other
Arkin Bio Ventures is part of Arkin Holdings, giving it access to a broad network and deep resources in healthcare. Founders benefit from this institutional backing, long-term capital, and deep connectivity across biotech, pharma, and the investor ecosystem. The fund is highly selective and typically leads or co-leads rounds.
Israel
